BCIS ACI 2020: CTO PCI Has No Prognostic Benefit - Is It a Waste of Time & Money?

Published: 07 February 2020

  • Views:

    Views Icon 224

  • Likes:

    Heart Icon 7
  • episode_image
    8m 28s
    Part 4 Panel Discussion
    Andrew Ladwiniec, Mark Gunning, Daniel J Blackman, James Spratt, Jonathan Hill, Rosemary Swallow
Average (ratings)
No ratings
Your rating

Overview

This video debate series filmed at the BCIS ACI meeting 2020, examines whether or not CTO PCI has any prognostic benefits. They examine the pros and cons for use and discuss if the advantages outweigh the cost. 

Thanks to BCIS for providing this footage

This content was provided by the courtesy of BCIS.

More from this programme

Part 1

Introduction and Preliminary Poll

Prof Mark Gunning (University Hospital of North Midlands, Stoke-on-Trent, UK) asks the audience to cast their vote on the proposition that “CTO PCI has no prognostic benefit and it is a waste of time and money”. Dr Andrew Ladwiniec (University Hospitals of Leicester NHS Trust, Leicester, UK) introduces the panel of the debate.
1 session
Introduction and Preliminary Poll Watch now

Part 2

Pro Argument

Dr Dan Blackman (Leeds Teaching Hospitals NHS Trust, Leeds, UK) argues that CTO PCI has no prognostic benefit and it is a waste of time and money.
1 session
Pro Argument Watch now

Part 3

Contra Argument

CTO PCI is often used to treat patients with chronic total occlusion (CTO), or complete blockages of the coronary arteries. Dr James Spratt (London Bridge Hospital, London, UK) argues for the cost-effectiveness and efficacy of percutaneous coronary intervention (PCI) for chronic total occlusion.
1 session
Contra Argument Watch now

Part 4

Panel Discussion

The panel and the chairs are concluding the debate by furthering the arguments of CTO PCI delivered by Dr Dan Blackman (Leeds Teaching Hospitals NHS Trust, Leeds, UK) and Dr James Spratt (London Bridge Hospital, London, UK).
1 session
Panel Discussion Watch now

Faculty Biographies

James Spratt

James Spratt

Professor of Interventional Cardiology

Prof James Spratt is a Professor of Interventional cardiology. A high-volume Interventional Cardiologist with an international reputation in complex PCI, with a sub-speciality interest in intravascular imaging and CTO. Widely published within this area and has performed live case demonstrations globally. He is interested in medical education and is the Founder of Optima Education. Prof James Spratt is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).

View full profile